KJM has received honoraria from Janssen, LEO Pharma, Lilly and Novartis. ADB consults lectures for Abbvie, Amgen, Boehringer Ingelheim, Celgene, Lilly, Novartis Pfizer. JNWN advisory boards at sponsored symposia together with grants research in the past 5 years AbbVie, Novartis, CEK and/or funding Galderma, GSK-Stiefel, Johnson & Johnson, Pfizer UCB Pharma. KM CEMG Actelion, Almirall, MSD, Pfiz...

In the real-world clinical setting, patients with moderate-to-severe ulcerative colitis (UC) may undergo dose escalation when they lose response to their prescribed biologic treatment. Such of agents has an impact on healthcare utilization and costs have patient outcomes. Currently, limited data exist that compare rates between anti-tumor necrosis factor (anti-TNF) therapies vedolizumab, a gut-...

Modern radiotherapy techniques heavily rely on high-quality medical imaging. PET provides biologic information about the tumor, complementary to anatomic imaging. Integrated PET/CT has found its way into the practice of radiation oncology, and (18)F-FDG PET is being introduced for radiotherapy planning. The functional information possibly augments accurate delineation and treatment of the tumor...

BACKGROUND Biologic therapies are widely used in inflammatory diseases, and they are associated to an increased infection risk, especially to granulomatous and intracellular infections such as Legionella. RESULTS A review of the literature revealed 105 cases of Legionella pneumonia in patients taking biologic therapies. Sixty-four patients (65.3%) were treated with infliximab, 23 (23.5%) with...

BACKGROUND Takayasu arteritis (TAK) is a large vessel vasculitis that rarely affects children. Data on childhood TAK are scarce. The aim of this study was to analyze the presenting features, course and outcome of children with TAK, compare efficacy of treatment regimens and identify high-risk factors for adverse outcome. METHODS A single-center cohort study of consecutive children fulfilling ...

Substantial progress has been made in our understanding of the immune system and immunopathogenesis of rheumatoid arthritis. This knowledge, combined with advances in biotechnology, has resulted in the development of biologic agents to selectively target elements of the immune system participating in the inflammatory response. This article reviews the available data from clinical trials of biol...

Serious infection is a concern for patients with psoriasis receiving biologic therapies. We assessed the risk of serious infections for biologics used to treat psoriasis by comparison with a cohort receiving non-biologic systemic therapies in a propensity score-weighted Cox proportional hazards model using data from the British Association of Dermatologists Biologic Interventions Register. Over...

OBJECTIVE The main objective was to compare the cost-effectiveness of therapeutic options in moderate or severe rheumatoid arthritis (RA) when a clinical response to a first TNF-blocker, either etanercept (ETA), adalimumab (ADA), or infliximab (INF), is insufficient. METHODS Effectiveness criteria were defined as remission (RS), low disease activity (LDAS), and moderate to high disease activi...